Skip to main content
. Author manuscript; available in PMC: 2024 Mar 26.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2022 Apr 20;22(8):e730–e737. doi: 10.1016/j.clml.2022.04.012

Table 2.

Efficacy

Best Response to Tisa-Cel No Bridging (n = 17), n (%) Bridging (n = 55), n (%) Overall (n = 72), n (%)
Complete response (CR) 5 (29.4) 20 (36.4) 25 (34.7)
Partial response (PR) 4 (23.5) 2 (3.6) 6 (8.3)
Stable disease (SD) 1 (5.9) 3 (5.5) 4 (5.6)
Progressive disease (PD) 7 (41.2) 30 (54.5) 37 (51.4)

Vital Status at Last Observation

Alive 12 (70.6) 37 (67.3) 49 (68.1)
Deceased 5 (29.4) 18 (32.7) 23 (31.9)